Brean Capital Raises Price Target on NuVasive (NUVA) to $70 Following Solid 2Q
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
NuVasive Reports Second Quarter 2016 Financial Results
July 26, 2016 4:02 PM EDTSAN DIEGO, CA -- (Marketwired) -- 07/26/16 -- NuVasive, Inc. (NASDAQ: NUVA), a leading medical device company focused on transforming spine surgery with minimally disruptive, procedurally-integrated solutions, announced today financial results for the quarter ended June 30, 2016.
Second Quarter 2016 Highlights
Revenue increased 16.4% to $236.2 million, or 16.1% on a constant currency basis;GAAP operating profit margin of 25.4%; Non-GAAP operating profit margin up 60 basis points from prior year to 15.9%;GAAP diluted earnings per share of $0.57; Non-GAAP diluted earnings per share up 28% from prior year to... More